The Japanese Pharmacopoeia Fifteenth Edition Shall Be Partially Amended As Follows:

Total Page:16

File Type:pdf, Size:1020Kb

The Japanese Pharmacopoeia Fifteenth Edition Shall Be Partially Amended As Follows: Description of content: The Japanese Pharmacopoeia Fifteenth edition shall be partially amended as follows: 1.To amend 1 article under the section of General Notice(List 1) 2.To amend 1 article under the section of General Rules for Crude Drugs(List 2) 3.To amend 5 articles under the section of General Rules for Preparations(List 3) 4.To establish 1 test method under the section of General Tests, Process and Apparatus (List 4) 5.To amend 9 test methods under the section of General Tests, Process and Apparatus(List 5) 6.To delete 6 monographs under the section of Monographs(List 6) 7.To establish 90 monographs under the section of Monographs(List 7) 8.To amend 171 monographs under the section of Monographs(List 8) List 1 9 List 2 1 List 3 (1)Extracts (2)Ophthalmic Ointments (3)Tinctures (4)Ophthalmic Solutions (5)Fluidextracts List 4 (1)Foreign Insoluble Matter Test for Ophthalmic Solutions List 5 (1)Qualitative Tests (2)Liquid Chromatography (3)Gas Chromatography (4)Water Determination (5)Optical Rotation Determination (6)Microbial Limit Test (7)Test for Metal Particles in Ophthalmic Ointments (8)Insoluble Particulate Matter Test for Injections (9)Dissolution Test List 6 (1)Sulfinpyrazone (2)Sulfinpyrazone Tablets (3)Tubocurarine Chloride Hydrochloride Hydrate (4)Tubocurarine Chloride Hydrochloride Injection (5)Fosfestrol (6)Fosfestrol Tablets List 7 (1)Aztreonam for Injection (2)Acemetacin (3)Azelastine Hydrochloride (4)Amikacin Sulfate Injection (5)Amlodipine Besilate (6)Amosulalol Hydrochloride (7)Amosulalol Hydrochloride Tablets (8)Alprostadil Injection (9)Alminoprofen (10)Alminoprofen Tablets (11)Ampicillin Sodium for Injection (12)Amlexanox (13)Amlexanox Tablets (14)Isoxsuprine Hydrochloride (15)Isoxsuprine Hydrochloride Tablets (16)Itraconazole (17)Ibudilast (18)Ubenimex (19)Etizolam Fine Granules (20)Etizolam Tablets (21)Enalapril Maleate (22)Enalapril maleate Tablets (23)Emorfazone (24)Erythromycin Enteric-Coated Tablets (25)Ozagrel Sodium (26)Ozagrel Sodium for Injection (27)Omeprazole (28)Griseofulvin Tablets (29)Clindamycin Phosphate Injection (30)L-Glutamine (31)Clobetasol Propionate (32)Clorazepate Dipotassium (33)Clorazepate Dipotassium Capsules (34)Chlorphenesin Carbamate Tablets (35)L-Cysteine (36)L-Cysteine Hydrochloride Hydrate (37)Zidovudine (38)Cibenzoline Succinate (39)Cibenzoline Succinate Tablets (40)Josamycin Tablets (41)Cilazapril Hydrate (42)Cilazapril Tablets (43)Cetirizine Hydrochloride (44)Cetirizine Hydrochloride Tablets (45)Cefazolin Sodium for Injection (46)Cefadroxil Capsules (47)Cefadroxil for Syrup (48)Ceftazidime for Injection (49)Cefmetazole Sodium for Injection (50)L-Serine (51)L-Tyrosine (52)Sodium Starch Glycolate (53)Doxorubicin Hydrochloride for Injection (54)Tobramycin Injection (55)Domperidone (56)Nafamostat Mesilate (57)Nabumetone (58)Nabumetone Tablets (59)Nizatidine (60)Nizatidine Capsules (61)Biotin (62)Bisoprolol Fumarate (63)Bisoprolol Fumarate Tablets (64)Piperacillin Hydrate (65)Felbinac (66)Bucillamine Tablets (67)Buprenorphine Hydrochloride (68)Buformine Hydrochloride (69)Buformine Hydrochloride Tablets (70)Buformine Hydrochloride Enteric-coated Tablets (71)Peplomycin Sulfate for Injection (72)Benzylpenicillin Potassium for Injection (73)Mitomycin C for Injection (74)Manidipine Hydrochloride (75)Manidipine Hydrochloride Tablets (76)Mizoribine (77)Mizoribine Tablets (78)Minocycline Hydrochloride for Injection (79)Labetalol Hydrochloride (80)Labetalol Hydrochloride Tablets (81)Rokitamycin Tablets (82)Powdered Turmeric (83)Powdered Corydalis Tuber (84)Keishibukuryogan Extract (85)Crataegus Fruit (86)Peucedanum Root (87)Aralia Rhizome (88)Hangekobokuto Extract (89)Lilium Bulb (90)Leonurus Herb List 8 (1)Ajmaline Tablets (2)Ascorbic Acid Injection (3)Acetylcholine Chloride for Injection (4)Amitriptyline Hydrochloride Tablets (5)Aminophyline Injection (6)L-Arginine Hydrochloride Injection (7)Idoxuridine Ophthalmic Solution (8)Imipramine Hydrochloride Tablets (9)Indometacin Capsules (10)Edrophonium Chloride Injection (11)Ephedrine Hydrochloride Tablets (12)Ephedrine Hydrochloride Injection (13)Calcium Chloride Hydrate (14)10% Sodium Chloride Injection (15)Fructose Injection (16)Gabexate Mesilate (17)Camostat Mesilate (18)Xylitol Injection (19)Sodium Citrate Injection for Transfusion (20)Creosote (21)Chlordiazepoxide Tablets (22)Chlorphenesin Carbamate (23)Chlorpropamide Tablets (24)Chlorpromazine Hydrochloride Tablets (25)Chlorpromazine Hydrochloride Injection (26)Salicylic Acid (27)Cyanocobalamin (28)Cyanocobalamin Injection (29)Cilostazol Tablets (30)Water for Injection (31)Suxamethonium Chloride Injection (32)Suxamethonium Chloride for Injection (33)Sultamicillin Tosilate Hydrate (34)Sulbactam Sodium (35)Sulpyrine Injection (36)Isotonic Sodium Chloride Solution (37)Cefatrizine Propylene Glycolate (38)Cefalotin Sodium (39)Talc (40)Sodium Bicarbonate Injection (41)Thiamine Chloride Hydrochloride Injection (42)Thiopental Sodium for Injection (43)Sodium Thiosulfate Injection (44)Tipepidine Hibenzate Tablets (45)Dextran 40 (46)Deslanoside Injection (47)Teceleukin for Injection (Genetical Recombination) (48)Dehydrocholic Acid Injection (49)Deferoxamine Mesilate (50)Dopamine Hydrochloride Injection (51)Trimetazidine Hydrochloride (52)Nicardipine Hydrochloride Injection (53)Nicotinic Acid Injection (54)Nicorandil (55)Anhydrous Lactose (56)Neostigmine Methylsulfate Injection (57)Noradrenaline Injection (58)Baclofen Tablets (59)Papaverine Hydrochloride Injection (60)Parnaparin Sodium (61)Bisacodyl Suppositories (62)Hydralazine Hydrochloride Tablets (63)Hypromellose Phthalate (64)Pyridoxine Hydrochloride Injection (65)Vincristine Sulfate (66)Famotidine for Injection (67)Faropenem Sodium Hydrate (68)Faropenem Sodium Tablets (69)Faropenem Sodium for Syrup (70)Glucose Injection (71)Prednisolone Sodium Succinate for Injection (72)Protamine Sulfate (73)Protamine Sulfate Injection (74)Betahistine Mesilate (75)Pethidine Hydrochloride Injection (76)Calcium Folinate (77)D-Mannitol Injection (78)Medazepam (79)Methyldopa Tablets (80)Mefruside Tablets (81)Morphine Hydrochloride Tablets (82)Folic Acid Tablets (83)Folic Acid Injection (84)Riboflavin Sodium Phosphate Injection (85)Magnesium Sulfate Injection (86)Ringer’s Solution (87)Anhydrous Dibasic Calcium Phosphate (88)Dibasic Calcium Phosphate Hydrate (89)Reserpine Injection (90)Levallorphan Tartrate Injection (91)Roxithromycin (92)Clematis Root (93)Termeric (94)Lindera Root (95)Uva Ursi Fluidextract (96)Corydalis Tuber (97)Scutellaria Root (98)Powdered Scutellaria Root (99)Coptis Rhizome (100)Powdered Coptis Rhizome (101)Polygala Root (102)Powdered Polygala Root (103)Polygonum Root (104)Zedoary (105)Kakkonto Extract (106)Japanese Valerian (107)Powdered Japanese Valerian (108)Kamishoyosan Extract (109)Processed Ginger (110)Glycyrrhiza Extract (111)Crude Glycyrrhiza Extract (112)Platycodon Fluidextract (113)Notopterygium (114)Apricot Kernel (115)Sophora Root (116)Powdered Sophora Root (117)Gentian (118)Powdered Gentian (119)Cyperus Rhizome (120)Powdered Cyperus Rhizome (121)Magnolia Bark (122)Powdered Magnolia Bark (123)Calumba (124)Powdered Calumba (125)Condurango Fluidextract (126)Asiasarum Root (127)Smilax Rhizome (128)Powdered Smilax Rhizome (129)Dioscorea Rhizome (130)Powdered Dioscorea Rhizome (131)Rehmannia Root (132)Lycium Bark (133)Lithospermum Root (134)Cimicifuga Rhizome (135)Senega (136)Powdered Senega (137)Cnidium Rhizome (138)Powdered Cnidium Rhizome (139)Nuphar Rhizome (140)Mulberry Bark (141)Perilla Herb (142)Panax Japonicus Rhizome (143)Powdered Panax Japonicus Rhizome (144)Anemarrhena Rhizome (145)Polyporus Sclerotium (146)Powdered Polyporus Sclerotium (147)Gastrodia Tuber (148)Asparagus Tuber (149)Peach Kernel (150)Powdered Peach Kernel (151)Ipecac (152)Powdered Ipecac (153)Fritillaria Bulb (154)Glehnia Root (155)Angelica Dahurica Root (156)Atractylodes Rhizome (157)Powdered Atractylodes Rhizome (158)Processed Aconite Root (159)Powdered Processed Aconite Root (160)Belladonna Extract (161)Imperata Rhizome (162)Saposhnikovia Root (163)Hochuekkito Extract (164)Nux Vomica Extract (165)Saussurea Root (166)Japanese Gentian (167)Powdered Japanese Gentian (168)Alpinia Officinarum Rhizome (169)Ryokeijutsukanto Extract (170)Scopolia Rhizome (171)Scopolia Extract .
Recommended publications
  • Prostaglandin D2 and the Role of the DP1, DP2 and TP Receptors in the Control of Airway Reflex Events
    ERJ Express. Published on October 16, 2014 as doi: 10.1183/09031936.00061614 ORIGINAL ARTICLE IN PRESS | CORRECTED PROOF Prostaglandin D2 and the role of the DP1, DP2 and TP receptors in the control of airway reflex events Sarah A. Maher1, Mark A. Birrell1,2, John J. Adcock1, Michael A. Wortley1, Eric D. Dubuis1, Sara J. Bonvini1, Megan S. Grace1 and Maria G. Belvisi1,2 Affiliations: 1Respiratory Pharmacology, National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London, UK. 2MRC and Asthma UK Centre in Allergic Mechanisms of Asthma, Imperial College London, London, UK. Correspondence: Maria G. Belvisi, Imperial College London, Respiratory Pharmacology, NHLI, Sir Alexander Fleming Building, Exhibition Road, London, SW7 2AZ, UK. E-mail: [email protected] ABSTRACT Prostaglandin D2 (PGD2) causes cough and levels are increased in asthma suggesting that it may contribute to symptoms. Although the prostaglandin D2 receptor 2 (DP2) is a target for numerous drug discovery programmes little is known about the actions of PGD2 on sensory nerves and cough. We used human and guinea pig bioassays, in vivo electrophysiology and a guinea pig conscious cough model to assess the effect of prostaglandin D2 receptor (DP1), DP2 and thromboxane receptor antagonism on PGD2 responses. PGD2 caused cough in a conscious guinea pig model and an increase in calcium in airway jugular ganglia. Using pharmacology and receptor-deficient mice we showed that the DP1 receptor mediates sensory nerve activation in mouse, guinea pig and human vagal afferents. In vivo, PGD2 and a DP1 receptor agonist, but not a DP2 receptor agonist, activated single airway C-fibres.
    [Show full text]
  • 4 Supplementary File
    Supplemental Material for High-throughput screening discovers anti-fibrotic properties of Haloperidol by hindering myofibroblast activation Michael Rehman1, Simone Vodret1, Luca Braga2, Corrado Guarnaccia3, Fulvio Celsi4, Giulia Rossetti5, Valentina Martinelli2, Tiziana Battini1, Carlin Long2, Kristina Vukusic1, Tea Kocijan1, Chiara Collesi2,6, Nadja Ring1, Natasa Skoko3, Mauro Giacca2,6, Giannino Del Sal7,8, Marco Confalonieri6, Marcello Raspa9, Alessandro Marcello10, Michael P. Myers11, Sergio Crovella3, Paolo Carloni5, Serena Zacchigna1,6 1Cardiovascular Biology, 2Molecular Medicine, 3Biotechnology Development, 10Molecular Virology, and 11Protein Networks Laboratories, International Centre for Genetic Engineering and Biotechnology (ICGEB), Padriciano, 34149, Trieste, Italy 4Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy 5Computational Biomedicine Section, Institute of Advanced Simulation IAS-5 and Institute of Neuroscience and Medicine INM-9, Forschungszentrum Jülich GmbH, 52425, Jülich, Germany 6Department of Medical, Surgical and Health Sciences, University of Trieste, 34149 Trieste, Italy 7National Laboratory CIB, Area Science Park Padriciano, Trieste, 34149, Italy 8Department of Life Sciences, University of Trieste, Trieste, 34127, Italy 9Consiglio Nazionale delle Ricerche (IBCN), CNR-Campus International Development (EMMA- INFRAFRONTIER-IMPC), Rome, Italy This PDF file includes: Supplementary Methods Supplementary References Supplementary Figures with legends 1 – 18 Supplementary Tables with legends 1 – 5 Supplementary Movie legends 1, 2 Supplementary Methods Cell culture Primary murine fibroblasts were isolated from skin, lung, kidney and hearts of adult CD1, C57BL/6 or aSMA-RFP/COLL-EGFP mice (1) by mechanical and enzymatic tissue digestion. Briefly, tissue was chopped in small chunks that were digested using a mixture of enzymes (Miltenyi Biotec, 130- 098-305) for 1 hour at 37°C with mechanical dissociation followed by filtration through a 70 µm cell strainer and centrifugation.
    [Show full text]
  • Cyclooxygenase Pathway
    Cyclooxygenase Pathway Diverse physical, chemical, Phospholipase A Glucocorticoids inflammatory, and 2 mitogenic stimuli NSAIDs NSAIDs Arachidonic Acid Prostaglandin G2 CYCLOOXYGENASE Prostaglandin G2 Prostaglandin H Prostaglandin H Synthase-1 Synthase-2 (COX 1) (COX 2) Prostaglandin H2 PEROXIDASE Prostaglandin H2 Tissue Specific Isomerases Prostacyclin Thromboxane A2 Prostaglandin D2 Prostaglandin E2 Prostaglandin F2α IP TPα, TPβ DP1, DP2 EP1, EP2, EP3, EP4 FPα, FPβ Endothelium, Kidney, Platelets, Vascular Mast Cells, Brain, Brain, Kidney, Vascular Uterus, Airways, Vascular Platelets, Brain Smooth Muscle Cells, Airways, Lymphocytes, Smooth Muscle Cells, Smooth Muscle Cells, Macrophages, Kidney Eosinophils Platelets Eyes Prostacyclin Item No. Product Features Prostacyclin (Prostaglandin I2; PGI2) is formed from arachidonic acid primarily in the vascular endothelium and renal cortex by sequential 515211 6-keto • Sample Types: Culture Medium | Plasma Prostaglandin • Measure 6-keto PGF levels down to 6 pg/ml activities of COX and prostacyclin synthase. PGI2 is non-enzymatically 1α F ELISA Kit • Incubation : 18 hours | Development: 90-120 minutes | hydrated to 6-keto PGF1α (t½ = 2-3 minutes), and then quickly converted 1α Read: Colorimetric at 405-420 nm to the major metabolite, 2,3-dinor-6-keto PGF1α (t½= 30 minutes). Prostacyclin was once thought to be a circulating hormone that regulated • Assay 24 samples in triplicate or 36 samples in duplicate platelet-vasculature interactions, but the rate of secretion into circulation • NOTE: A portion of urinary 6-keto PGF1α is of renal origin coupled with the short half-life indicate that prostacyclin functions • NOTE : It has been found that normal plasma levels of 6-keto PGF may be low locally.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Effect of TTC-909 on Cerebral Infarction Following Permanent Occlusion of the Middle Cerebral Artery in Stroke Prone Spontaneously Hypertensive Rats
    J Pharmacol Sci 91, 305 – 312 (2003) Journal of Pharmacological Sciences ©2003 The Japanese Pharmacological Society Full Paper Effect of TTC-909 on Cerebral Infarction Following Permanent Occlusion of the Middle Cerebral Artery in Stroke Prone Spontaneously Hypertensive Rats Yasuko Karasawa1, Hiroko Komiyama1, Shigeru Yoshida1, Noriko Hino1, Yasuhiro Katsuura2, Shiro Nakaike1 and Hiroaki Araki3,* 1Pharmacology Laboratory, Research Center, Taisho Pharmaceutical Co., Ltd., Yoshino-cho 1-403, Saitama 330-8530, Japan 2Pharmacological Research Department, Teijin Ltd., 4-3-2 Asahigaoka, Hino, Tokyo 191-8512, Japan 3Department of Hospital Pharmacy, Ehime University School of Medicine, Shiktsukawa, Shigenobu-cho, Onsen-gun, Ehime 791-0295, Japan Received November 14, 2002; Accepted January 30, 2003 Abstract. We investigated the effect of TTC-909, a drug preparation of the stable prostaglandin I2 analogue clinprost (isocarbacyclin methylester; methyl 5-{(1S,5S,6R,7R)-7- hydroxy-6-[(E)-(S)-3-hydroxy-1-octenyl] bicyclo[3.3.0]oct-2-en-3-yl} pentanoate) incorporated into lipid microspheres, on cerebral infarction 7 days after permanent occlusion of the middle cerebral artery (MCA) in stroke prone spontaneously hypertensive rats (SHRSP). Under the anesthesia, the MCA was permanently occluded above the rhinal fissure. In schedule 1, vehicle or TTC-909 was injected i.v. once daily over 7 days starting immediately after MCA occlusion. In schedule 2, vehicle or TTC-909 was infused for 3 h starting immediately after MCA occlusion. In schedule 3, vehicle or TTC-909 was infused for 3 h starting immediately after MCA occlusion followed by bolus injection once daily over 6 days. Seven days later, the infarct volume was estimated following hematoxylin and eosin staining.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Efficacy of Different Types of Therapy for COVID-19
    life Review Efficacy of Different Types of Therapy for COVID-19: A Comprehensive Review Anna Starshinova 1,*, Anna Malkova 2 , Ulia Zinchenko 3 , Dmitry Kudlay 4,5 , Anzhela Glushkova 6, Irina Dovgalyk 3, Piotr Yablonskiy 2,3 and Yehuda Shoenfeld 2,7,8 1 Almazov National Medical Research Centre, Head of the Research Department, 2 Akkuratov Str., 197341 Saint-Petersburg, Russia 2 Medical Department, Saint Petersburg State University, 199034 Saint-Petersburg, Russia; [email protected] (A.M.); [email protected] (P.Y.); [email protected] (Y.S.) 3 St. Petersburg Research Institute of Phthisiopulmonology, 199034 Saint-Petersburg, Russia; [email protected] (U.Z.); [email protected] (I.D.) 4 NRC Institute of Immunology FMBA of Russia, 115478 Moscow, Russia; [email protected] 5 Medical Department, I.M. Sechenov First Moscow State Medical University, 119435 Moscow, Russia 6 V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology, 192019 Saint Petersburg, Russia; [email protected] 7 Ariel University, Kiryat HaMada 3, Ariel 40700, Israel 8 Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 5265601, Israel * Correspondence: [email protected]; Tel.: +7-9052043861 Citation: Starshinova, A.; Malkova, Abstract: A new coronavirus disease (COVID-19) has already affected millions of people in 213 coun- A.; Zinchenko, U.; Kudlay, D.; tries. The possibilities of treatment have been reviewed in recent publications but there are many Glushkova, A.; Dovgalyk, I.; controversial results and conclusions. An analysis of the studies did not reveal a difference in Yablonskiy, P.; Shoenfeld, Y. Efficacy mortality level between people treated with standard therapy, such as antiviral drugs and dexam- of Different Types of Therapy for ethasone, and new antiviral drugs/additional immune therapy.
    [Show full text]
  • Nicotine in High Concentration Causes Contraction of Isolated Strips of Rabbit Corpus Cavernosum
    Korean J Physiol Pharmacol Vol 19: 257-262, May, 2015 pISSN 1226-4512 http://dx.doi.org/10.4196/kjpp.2015.19.3.257 eISSN 2093-3827 Nicotine in High Concentration Causes Contraction of Isolated Strips of Rabbit Corpus Cavernosum Hoai Bac Nguyen1, Shin Young Lee2, Soo Hyun Park3, Jun Hyun Han4, Moo Yeol Lee3,*, and Soon Chul Myung1,* 1Advanced Urogenital Disease Research Center; Research Institute for Translational System Biomics; Department of Urology, Chung-Ang University Hospital, Seoul 156-755, 2Department of Urology, Seoul Medical Center, Seoul 131-795, 3Department of Physiology, College of Medicine, Chung-Ang University, Seoul 156-756, 4Department of Urology, Hallym University Dongtan Sacred Heart Hospital, Hwaseong 445-170, Korea It is well known that cigarette smoke can cause erectile dysfunction by affecting the penile vascular system. However, the exact effects of nicotine on the corpus cavernosum remains poorly understood. Nicotine has been reported to cause relaxation of the corpus cavernosum; it has also been reported to cause both contraction and relaxation. Therefore, high concentrations of nicotine were studied in strips from the rabbit corpus cavernosum to better understand its effects. The proximal penile corpus cavernosal strips from male rabbits weighing approximately 4 kg were used in organ bath studies. Nicotine in high concentrations (10-5∼10-4 M) produced dose-dependent contractions of the corpus cavernosal strips. The incubation with 10-5 M hexamethonium (nicotinic receptor antagonist) significantly inhibited the magnitude of the nicotine associated contractions. The nicotine-induced contractions were not only significantly inhibited by pretreatment with 10-5 M indomethacin (nonspecific cyclooxygenase inhibitor) and with 10-6 M NS-398 (selective cyclooxygenase inhibitor), but also with 10-6 M Y-27632 (Rho kinase inhibitor).
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Multidrug Treatment with Nelfinavir and Cepharanthine Against COVID-19
    Supplemental Information Multidrug treatment with nelfinavir and cepharanthine against COVID-19 Hirofumi Ohashi1,2,¶, Koichi Watashi1,2,3,4*, Wakana Saso1,5.6,¶, Kaho Shionoya1,2, Shoya Iwanami7, Takatsugu Hirokawa8,9,10, Tsuyoshi Shirai11, Shigehiko Kanaya12, Yusuke Ito7, Kwang Su Kim7, Kazane Nishioka1,2, Shuji Ando13, Keisuke Ejima14, Yoshiki Koizumi15, Tomohiro Tanaka16, Shin Aoki16,17, Kouji Kuramochi2, Tadaki Suzuki18, Katsumi Maenaka19, Tetsuro Matano5,6, Masamichi Muramatsu1, Masayuki Saijo13, Kazuyuki Aihara20, Shingo Iwami4,7,21,22,23, Makoto Takeda24, Jane A. McKeating25, Takaji Wakita1 1Department of Virology II, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 2Department of Applied Biological Science, Tokyo University of Science, Noda 278-8510, Japan, 3Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan, 4MIRAI, JST, Saitama 332-0012, Japan, 5The Institute of Medical Science, The University of Tokyo, Tokyo 108-8639, Japan, 6AIDS Research Center, National Institute of Infectious Diseases, Tokyo 162-8640, Japan, 7Department of Biology, Faculty of Sciences, Kyushu University, Fukuoka 812-8581, Japan, 8Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tokyo 135-0064, Japan, 9Division of Biomedical Science, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan, 10Transborder Medical Research Center, University of Tsukuba, Tsukuba 305-8575, Japan, 11Faculty of Bioscience, Nagahama Institute
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • The Efficacy of Ozagrel Sodium As a Rescue Or Prophylaxis in The
    Research Article World Journal of Vascular Surgery Published: 16 Mar, 2018 The Efficacy of Ozagrel Sodium as a Rescue or Prophylaxis in the Perioperative Management of Thromboembolism during Coil Embolization of Ruptured and Unruptured Cerebral Aneurysms Yasuhiro Kawabata*, Norio Nakajima and Hidenori Miyake Department of Neurosurgery, Kyoto Katsura Hospital, Japan Abstract Objectives: Thromboembolism is the leading cause of neurological complication in neurointervention. We retrospectively analyzed the incidence and the outcome of thromboembolism and the efficacy of ozagrel sodium during coiling embolization of saccular cerebral aneurysm. Materials and Methods: Since 2012, we treated 103 patients with 106 aneurysms, in whom 116 procedures were performed. 35 patients were male, and 68 patients were female. The median age was 66.5 years (range 21 to 88). Sixty-two aneurysms were ruptured, and 44 aneurysms were unruptured. In a patient, coil embolization of a ruptured aneurysm and an unruptured aneurysm was performed simultaneously. Retreatment was performed in 12 patients. Ozagrel sodium, a thromboxane A2 synthase inhibitor, was administered as a rescue in 8 patients and as a prophylaxis in 17 patients prior to or during the procedure, and thrombectomy using Penumbra system® was performed in a patient. Functional outcome was assessed using Modified Rankin Scale (MRS). OPEN ACCESS Results: Thromboembolic events occurred in 27 procedures (23.3%), in 13 of which *Correspondence: thromboembolism were symptomatic. Cerebral artery occlusion was observed in 9 patients during Yasuhiro Kawabata, Department of and after the procedure, in 6 of whom early recanalization could be achieved. Procedure-related Neurosurgery, Kyoto Social Welfare permanent neurological deficit due to thromboembolism was observed in 6 patients (5.2%) Foundation, Kyoto Katsura Hospital, 17 exclusively in ruptured group; three of them had fair outcome of MRS 2-3 and other three patients Yamada Hirao-cho, Nishikyo-ku, Kyoto, had poor outcome unrelated to thromboembolism.
    [Show full text]